ART during tuberculosis therapy reduces mortality risk for people with HIV
Bedaquiline as part of tailored therapy for MDR- and XDR-TB achieves impressive culture conversion rates
Use of drug susceptibility testing to select therapy improves treatment outcomes in patients with MDR- and XDR-TB
Reduced treatment delays for people with drug-resistant TB and HIV co-infection through decentralised care and rapid Xpert MTB/RIF test
Novel TB regimen could reduce treatment duration
